SS-31 (Elamipretide)

Overview

SS-31, also known as elamipretide (and previously as Bendavia and MTP-131), is a synthetic cell-permeable tetrapeptide developed by Hazel Szeto and Peter Bhatt Schiller at Weill Cornell Medical College. The "SS" designation stands for "Szeto-Schiller," referencing its creators. SS-31 belongs to a family of Szeto-Schiller peptides (SS-01, SS-02, SS-20, SS-31) that were designed to concentrate selectively in mitochondria due to their alternating aromatic-cationic amino acid motif.

What distinguishes SS-31 from the broader Szeto-Schiller peptide family — and from virtually all other mitochondria-targeted compounds — is its specific interaction with cardiolipin, a unique phospholipid found exclusively in the inner mitochondrial membrane. Cardiolipin plays an essential structural and functional role in electron transport chain (ETC) complex assembly, cristae morphology, and mitochondrial bioenergetics. Dysfunction or loss of cardiolipin is a common feature of mitochondrial disease, heart failure, neurodegeneration, and aging.

SS-31 represents the most clinically advanced mitochondria-targeted peptide therapeutic. It has undergone extensive clinical testing, including Phase III trials for Barth syndrome (a rare genetic cardiolipin deficiency disorder) and multiple Phase II trials for heart failure, primary mitochondrial myopathy, age-related macular degeneration, and renal ischemia-reperfusion injury. In December 2023, Stealth BioTherapeutics (now a subsidiary of Larimar Therapeutics as of 2024 reorganization) reported that elamipretide met its primary endpoint in the TAZPOWER trial for Barth syndrome, representing a landmark for mitochondrial medicine.

Structure and Sequence

Sequence: D-Arg-Dmt-Lys-Phe-NH₂

• Molecular formula: C₃₂H₄₉N₉O₅
• Molecular weight: 639.8 g/mol
• Composition: Four amino acids in an alternating aromatic-cationic motif
  • D-Arg — D-isomer of arginine (cationic); D-configuration enhances protease resistance
  • Dmt — 2',6'-dimethyltyrosine (aromatic); unnatural amino acid providing enhanced lipophilicity and antioxidant properties
  • Lys — lysine (cationic)
  • Phe-NH₂ — phenylalanine amide (aromatic)
• Net charge: +3 at physiological pH
• C-terminal amidation: Enhances stability and membrane interaction
• Key structural features: The alternating cationic-aromatic motif enables mitochondrial targeting without requiring the large lipophilic cation (e.g., TPP+) used by other mitochondria-targeted molecules

SS-31 concentrates in mitochondria approximately 1,000-5,000-fold relative to cytoplasm. Critically, this accumulation is not driven by mitochondrial membrane potential (unlike TPP+-based compounds), meaning SS-31 targets mitochondria even in depolarized (dysfunctional) organelles — a key advantage for treating mitochondrial disease.

Mechanism of Action

Cardiolipin Interaction

SS-31's primary mechanism is selective binding to cardiolipin (CL) in the inner mitochondrial membrane:

• Cardiolipin is a unique diphosphatidylglycerol lipid found almost exclusively in the inner mitochondrial membrane, where it constitutes approximately 15-20% of total phospholipid content
• SS-31 interacts with cardiolipin through electrostatic (cationic residues with anionic CL headgroups) and hydrophobic (aromatic residues with CL acyl chains) interactions
• This interaction stabilizes the native CL-protein interactions that are essential for ETC complex assembly and supercomplex formation
• SS-31 does not scavenge free radicals directly at the concentrations achieved in vivo; rather, it prevents excess ROS generation by optimizing electron transport

Electron Transport Chain Optimization

Through cardiolipin stabilization, SS-31:

• Stabilizes ETC supercomplexes — Complexes I, III, and IV assemble into supercomplexes (respirasomes) on a cardiolipin platform; SS-31 maintains this architecture
• Improves electron transfer efficiency — Reduced electron leak from Complex I and III decreases superoxide generation
• Maintains Complex IV (cytochrome c oxidase) function — Cardiolipin-cytochrome c interaction is essential for Complex IV activity; SS-31 preserves this interaction
• Restores ATP synthesis — By optimizing ETC function, SS-31 improves the efficiency of oxidative phosphorylation

Cristae Morphology Preservation

Cardiolipin is essential for the formation and maintenance of mitochondrial cristae — the invaginations of the inner membrane where ETC complexes are concentrated:

• SS-31 prevents cristae remodeling and loss that occurs in mitochondrial disease and aging
• Preserved cristae architecture maintains the electrochemical gradient efficiency for ATP synthesis
• Electron microscopy studies have demonstrated that SS-31 treatment restores normal cristae morphology in diseased mitochondria

Cytochrome c Interaction

SS-31 modulates the cardiolipin-cytochrome c interaction:

• Cytochrome c binds to cardiolipin at two sites; tight binding can convert cytochrome c from an electron carrier to a peroxidase
• SS-31 competes with cytochrome c for cardiolipin binding, maintaining cytochrome c in its electron-carrying (non-peroxidase) conformation
• This prevents cardiolipin peroxidation, which is an early event in apoptotic signaling

Research Summary

Pharmacokinetics

SS-31 has well-characterized pharmacokinetics from clinical trials:

• Half-life: Approximately 3-4 hours following subcutaneous administration in humans
• Bioavailability: Approximately 80-90% via subcutaneous injection
• Peak plasma concentration: Reached within 30-60 minutes post-subcutaneous dose
• Mitochondrial concentration: Achieves 1,000-5,000-fold concentration in mitochondria relative to cytoplasm
• Membrane potential independence: Unlike TPP+-conjugated compounds, SS-31 accumulates in mitochondria regardless of membrane potential — critical for diseased mitochondria
• Cell permeability: Rapidly cell-permeable without requiring active transport
• Metabolism: Metabolized by tissue peptidases; D-Arg and Dmt modifications provide significant protease resistance
• Clinical dosing: 4 mg/day subcutaneous injection (Barth syndrome trials); 40 mg IV infusion (heart failure acute trials)
• D-amino acid advantage: The D-Arg residue provides substantial resistance to aminopeptidase degradation, contributing to the clinically practical half-life

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Dosing Schedule

Syringe Measurements (U-100 insulin syringe)

Cycle Guidelines

• Cycle length: 8-12 weeks
• Route: Subcutaneous injection
• Timing: Consistent daily timing; rotate injection sites
• Injection sites: Rotate between abdomen, thighs, upper arms, and buttocks
• Split doses: Space injections at least 2 inches apart; inject slowly over 3-5 seconds
• Note: Limited data beyond 12 weeks of continuous use

Common Discussion Topics

1. Barth syndrome treatment — SS-31 (elamipretide) is the first and most advanced pharmacotherapy specifically targeting the cardiolipin deficiency underlying Barth syndrome
2. Heart failure applications — Clinical data in both acute MI and chronic heart failure with reduced ejection fraction has generated substantial cardiology interest
3. Mitochondrial medicine paradigm — SS-31 represents the concept of treating mitochondrial dysfunction directly rather than managing downstream symptoms
4. Aging and mitochondrial decline — Preclinical reversal of age-related mitochondrial dysfunction in heart, skeletal muscle, and kidney positions SS-31 in the aging research discussion
5. Comparison with other MDPs — Discussed alongside humanin and MOTS-c as complementary approaches to mitochondrial support, though SS-31 is synthetic rather than endogenous
6. Cardiolipin biology — SS-31 research has elevated awareness of cardiolipin's central role in mitochondrial function and disease, driving interest in cardiolipin-targeted therapeutics

Limitations of Current Research

1. Regulatory pathway complexity — Despite positive Phase III data in Barth syndrome, the regulatory approval pathway for rare disease indications can be complex; elamipretide has faced FDA review challenges
2. Patient population size — Barth syndrome is ultra-rare (approximately 1 in 300,000-400,000 births), limiting trial size and statistical power
3. Heart failure trial mixed results — Not all heart failure trial endpoints have been met; larger Phase III heart failure studies would be needed for that indication
4. Cost and access — As a specialty pharmaceutical, elamipretide is expected to carry significant cost
5. Long-term safety data — While short-to-medium-term safety profiles are favorable, long-term consequences of chronic cardiolipin modulation remain to be characterized

Related Compounds

• Humanin — a mitochondrial-derived peptide with neuroprotective and anti-apoptotic properties
• MOTS-c — a mitochondrial-derived peptide focused on metabolic regulation and AMPK activation
• MitoQ — a ubiquinone conjugated to triphenylphosphonium (TPP+); a mitochondria-targeted antioxidant that relies on membrane potential for accumulation
• SkQ1 (Visomitin) — a plastoquinone-based mitochondria-targeted antioxidant; approved in Russia for dry eye
• Idebenone — a synthetic CoQ10 analog used in Friedreich's ataxia and Leber hereditary optic neuropathy
• NAD+ precursors (NMN, NR) — compounds that support mitochondrial function through a different mechanism (NAD+ repletion)